HYPERTROPHIC CARDIOMYOPATHY IN ICELAND IS CHARACTERIZED BY LOW EVENT RATE CLINICAL COURSE AND MYBPC3 FOUNDER MUTATION

Berglind Adalsteinsdottir,Polakit Teekakirikul,Barry Maron,Daniel F. Gudbjartsson,Hilma Holm,Michael Burke,Ragnar Danielsen,Christine Seidman,Jonathan G. Seidman,Gunnar Gunnarsson

HYPERTROPHIC CARDIOMYOPATHY IN ICELAND IS CHARACTERIZED BY LOW EVENT RATE CLINICAL COURSE AND MYBPC3 FOUNDER MUTATION

2014

Berglind Adalsteinsdottir
Polakit Teekakirikul
Barry Maron
Daniel F. Gudbjartsson
Hilma Holm
Michael Burke
Ragnar Danielsen
Christine Seidman
Jonathan G. Seidman
Gunnar Gunnarsson

The aim of this study was to define the clinical and genetic characteristics of hypertrophic cardiomyopathy (HCM) in Iceland. All HCM patients in Iceland between 1997-2010 were identified and invited for clinical assessment and genetic testing. Phenotypes were obtained from medical records and

Keywords:

Founder mutation
Medical record
Genetic testing
Hypertrophic cardiomyopathy
Diabetes mellitus
Internal medicine
Cardiology
Medicine
clinical course

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations